Immunic Appoints Biopharma Veteran Michael W. Bonney as Board Chair
IMUX has more than doubled off its 52-week low of $5.062.
Summary
Immunic, Inc. has appointed Michael W. Bonney, a seasoned biopharmaceutical executive with deep experience in multiple sclerosis commercialization, as the new Chair of its Board of Directors.
Key Events · Executive and Board Changes · IMUX
-
New Board Chair Appointed
Michael W. Bonney has been appointed as Chair of the Board of Directors, effective May 16, 2026.
-
Extensive Biopharma Experience
Mr. Bonney brings over 30 years of leadership, including senior commercial roles at Biogen (involved in Avonex® launch for MS) and CEO of Cubist Pharmaceuticals (acquired by Merck for $9.5 billion). His MS and commercialization expertise is highly relevant to Immunic's late-stage pipeline.
-
Equity Grant for New Chair
In connection with his appointment, Mr. Bonney received an inaugural grant of options to purchase 100,000 shares of common stock, vesting over three years, subject to shareholder approval.
-
Board Structure Update
Simona Skerjanec transitions from Interim Chairperson to a regular Board member, and the Board size has increased from nine to ten members.
Analysis · IMUX · Life Sciences
The appointment of Michael W. Bonney as Chair of the Board is a significant strategic move for Immunic. His extensive experience in biopharmaceutical commercialization, particularly with the successful launch of Avonex for multiple sclerosis, directly aligns with Immunic's lead program, vidofludimus calcium, which is in late-stage clinical trials for MS. This leadership addition strengthens the company's expertise as it approaches potential regulatory approval and commercialization.
At the time of this filing, IMUX was trading at $12.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.8M. The 52-week trading range was $5.06 to $15.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.